INHIBIKASE THERAPEUTICS INC
Public company snapshot, recent ticker-linked headlines, and a path into evidence-backed AI research.
Latest price
$1.55
-7.19%
Alpha Vantage · 10/30/2026
One-year price history
Adjusted daily closes · 252 observations · as of Oct 30, 2026
1 month
-19.7%
3 months
-29.9%
6 months
-18.9%
1 year
+6.2%
Year to date
-24.4%
52-week range
$1.41 – $2.52
Fundamental snapshot
Latest reported period: Jun 30, 2026
Market cap
$216.3M
P/E
-3.6
P/B
1.4
P/S
—
Revenue
$0
Net income
-$60.64M
Diluted EPS
-0.43
Gross margin
—
Net margin
—
Return on equity
-42.80%
Total debt
$0
Cash
$31.21M
Free cash flow
-$42.61M
Latest eight reported quarters
Reported quarterly values, newest first
| Period | Revenue | Net income | Gross margin | Net margin | Free cash flow |
|---|---|---|---|---|---|
| Jun 30, 2026 | $0 | -$19.59M | — | — | -$12.44M |
| Mar 31, 2026 | $0 | -$16.38M | — | — | -$12.06M |
| Dec 31, 2025 | $0 | -$12.73M | — | — | -$7.52M |
| Sep 30, 2025 | $0 | -$11.93M | — | — | -$10.59M |
| Jun 30, 2025 | $0 | -$9.92M | — | — | -$5.57M |
| Mar 31, 2025 | $0 | -$13.68M | — | — | -$4.12M |
| Dec 31, 2024 | $0 | -$12.13M | — | — | -$5.35M |
| Sep 30, 2024 | $0 | -$5.78M | — | — | -$4.88M |
Reported figures can reflect company reporting conventions, restatements, or sector-specific accounting. Verify against filings before relying on a valuation comparison.
Recent IKT news
All market newsNo ticker-linked stories are in the current archive.